Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aprile Gilmore

Pediatrics Hattiesburg, MS Medical Doctor

NPI 1144517541 CMS profile 395739

4210 Lincoln Rd, Hattiesburg, MS 39402

Open in the dashboard

General payments

$4,003

253 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aprile Gilmore of Hattiesburg, MS is reported in the CMS Open Payments database as having received $4,003 across 253 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $867 54
2024 General $905 61
2023 General $605 47
2022 General $452 24
2021 General $648 33
2020 General $106 6
2019 General $420 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aprile Gilmore
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Aprile Gilmore were reported at $867. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Aprile Gilmore Pediatrics median Middle half National median
2019 $420 $86 $31–$183 $163
2020 $106 $49 $22–$110 $114
2021 $648 $68 $27–$158 $132
2022 $452 $77 $30–$173 $149
2023 $605 $88 $33–$190 $160
2024 $905 $94 $34–$206 $164
2025 $867 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $470 51 payments
  2. Corium, Inc. $454 27 payments
  3. Supernus Pharmaceuticals, Inc. $436 19 payments
  4. Pfizer Inc. $400 25 payments
  5. Tris Pharma Inc $375 22 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $288 14 payments
  7. Merck Sharp & Dohme Corporation $251 16 payments
  8. GlaxoSmithKline, LLC. $232 16 payments
  9. Collegium Pharmaceutical, Inc. $213 20 payments
  10. Sobi, Inc $152 8 payments
  11. Other $731 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,808 249 payments
  2. Debt forgiveness $167 3 payments
  3. Education $28 1 payment
Products named General payments · program years 2019–2025
  1. Azstarys $454 27 payments
  2. JORNAY PM Central Nervous System Stimulant $401 47 payments
  3. Qelbree $362 16 payments
  4. VYVANSE $335 19 payments
  5. TRUMENBA $266 17 payments
  6. BEXSERO $232 16 payments
  7. GARDASIL 9 $228 14 payments
  8. Jornay PM Adhd $213 20 payments
  9. VAXNEUVANCE $202 12 payments
  10. PEDIARIX $197 14 payments
  11. Other $2,537 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

253 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record